Observation of the effect of combined levonorgestrel intrauterine sustained-release system after lesion resection in the treatment of patients with protruding uterine adenomyoma
病灶切除术后联合左炔诺孕酮宫内缓释系统治疗内突型子宫腺肌瘤患者的效果观察

摘要

目的 探析病灶切除术后联合左炔诺孕酮宫内缓释系统治疗内突型子宫腺肌瘤的临床价值和使用意义。方法 选择我院2023年2月-2024年2月，一年间收治的30例内突型子宫腺肌瘤患者作为研究对象。将患者按照治疗方法的不同随机分为对照组（15例，使用病灶切除术治疗）和研究组（15例，实施病灶切除术后联合左炔诺孕酮宫内缓释系统治疗）。对两组患者的治疗效果进行收集和分析。结果 两组患者在治疗后均取得一定效果，研究组患者VAS、PBAC评分以及E2、LH、FSH水平均相对于对照组显著更低，差异具有统计学上的显著性（P＜0.05）。结论 病灶切除术后联合左炔诺孕酮宫内缓释系统治疗对内突型子宫腺肌瘤患者具备显著的临床效果，能够有效改善患者的月经情况，有较高的应用价值。

Abstract

Objective To explore the clinical value and significance of using levonorgestrel intrauterine sustained-release system in the treatment of protruding uterine adenomyoma after lesion resection.
Methods Fifty patients with protruding uterine adenomyoma admitted to our hospital from September 2022 to September 2023 were selected as the study subjects. Patients were randomly divided into a control group (25 cases, treated with lesion resection) and a study group (25 cases, treated with lesion resection combined with levonorgestrel intrauterine sustained-release system) according to different treatment methods. Collect and analyze the treatment outcomes of two groups of patients.
Results Both groups of patients achieved certain results after treatment. The VAS, PBAC scores, E2, LH, and FSH levels in the study group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05).
Conclusion   The combined use of levonorgestrel intrauterine sustained-release system after lesion resection has significant clinical effects on patients with protruding uterine adenomyoma, effectively improving their menstrual status, and has high application value.